Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non-Platinum-Containing Regimens, and Molecular Targeted Agents

Table 3

Main clinical trials implementing molecular targeted agents concurrently with external beam irradiation in patients with locally advanced cervical cancer.

Trial	Year	Phase	Experimental regimen	𝑁	FIGO stage	Primary outcome	Remarks
Nogueira-Rodrigues et al. [44]	2008	I	Erlotinib	15	IIB-IIIB	Feasible	Recommended erlotinib dose: 150 mg
Moore et al. [45]	2012	I	Cetuximab	>20	IIA-IVA	Feasible	Not feasible in patients with extended field radiation therapy
Schefter et al. [46]	2012	I-II	Bevacizumab; Cisplatin	60	IB-IIIB	Feasible	Hematologic toxicity common

FIGO: International Federation of Gynecologic Oncology.